Biotech News

PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

PTC Therapeutics, Inc. (PTCT)PTC Therapeutics, Inc.2026-04-28 20:05 ESTClinical readout

- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose - - Continued evidence of favorable safety profile - - Novartis initiated global Phase 3 INVEST-HD study of votoplam - - PTC will host a conference call to discuss

Open original release

Related news

CAPRCapricor Therapeutics2025-12-16 21:05 EST

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy

TARAProtara Therapeutics2026-05-15 11:00 EST

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC

TARAProtara Therapeutics2026-04-27 20:05 EST

Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting

PTCTPTC Therapeutics, Inc.2026-04-28 13:28 EST

PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study

PTCTPTC Therapeutics, Inc.2026-04-22 12:00 EST

PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026

KRYSKrystal Biotech2026-01-08 21:01 EST

Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis

KRYSKrystal Biotech2026-01-07 21:05 EST

Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis

CRNXCrinetics Pharmaceuticals2026-01-04 21:00 EST

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

MNPRMonopar2026-06-26 20:05 EST

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease

CAPRCapricor Therapeutics2026-06-26 13:05 EST

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

View all latest news

PTC Therapeutics, Inc.

PTC Therapeutics is a biopharmaceutical company focused on rare disease and gene-related therapies. Its story combines commercial products with a pipeline aimed at genetically defined conditions.

Recent company news

PTCTPTC Therapeutics, Inc.2026-05-07 20:01 EST

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

PTCTPTC Therapeutics, Inc.2026-05-04 12:00 EST

PTC Therapeutics to Participate in Upcoming Investor Conferences

PTCTPTC Therapeutics, Inc.2026-04-28 20:05 EST

PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

PTCTPTC Therapeutics, Inc.2026-04-28 13:28 EST

PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study

PTCTPTC Therapeutics, Inc.2026-04-22 12:00 EST

PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026

Stock data

Close: 75.80 USD
Market cap: 5.66B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States